Epigenetic Rejuvenation in the Eye Sets Stage for Reversing Blindness

Scientists report that epigenetic reprogramming to revive youthful cellular memory in aging eye cells has reached humans, with the first patient treated in a Phase 1 trial for glaucoma and other optic neuropathies. The approach could someday restore some lost vision, but safety, delivery, and how durable the effects are remain major hurdles before it becomes a widely available therapy.